Ataluren
Translarna (ataluren) is a small molecule pharmaceutical. Ataluren was first approved as Translarna on 2014-07-31. It has been approved in Europe to treat duchenne muscular dystrophy.
| Trade Name | Translarna |
|---|---|
| Common Name | Ataluren |
| Indication | duchenne muscular dystrophy |
| Drug Class | Inducers of ribossomal readthrough of nonsense mutation mRNA stop codons |
